Esperion plummets after updating CVOT timeline

Esperion Therapeutics Inc. (NASDAQ:ESPR) lost $16.76 (48%) to $18.33 on Tuesday after reporting after market close Monday that "any concern regarding the benefit/risk assessment of ETC-1002 could necessitate" that the company complete a cardiovascular outcomes trial (CVOT) before approval. Esperion had said last month that FDA would not demand a pre-approval CVOT. ...